American Hospital Association (AHA)

This page includes news from the American Hospital Association (AHA) is a healthcare industry trade group representing hospitals and healthcare providers and a key source of information on healthcare issues, trends and advocacy in legislation. Nearly 5,000 hospitals, health care systems, networks, other providers of care and 43,000 individual members come together to form the AHA. AHA ensures that members' perspectives and needs are heard and addressed in national health policy development, legislative and regulatory debates, and judicial matters.

RSS icon
Thumbnail

Industry reactions to interoperability rule are a mixed bag

A set of new rules that aim to improve the interoperability of healthcare records and set a string of new requirements on healthcare providers was met with mixed reactions across the industry.

Thumbnail

Hospitals largely supportive of 2019 IPPS proposed rule

Fewer quality measures, a shorter reporting period for Meaningful Use requirements and an increase in uncompensated rate payments were all positives in the eyes of hospitals in their initial reaction to the proposed 2019 Medicare Inpatient Prospective Payment System (IPPS) rule.

Displaying 33 - 34 of 34

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.